Top KOLs Discussing DESTINY-Lung04
DESTINY-Lung04 Key Slides & Visuals
DESTINY-Lung04 Top Tweets
𝕏HER2-mutant NSCLC landscape at #TTLC2026 by Dr. Christina Paik👇 In previously treated pts, three FDA approved drugs: T-DXd, Zongertinib, Sevabertinib. 1L phase 3 trials ongoing: DESTINY-Lung04, Beamion LUNG-2 m, SOHO-02. https://t.co/f9meok1tFL
𝕏JUST IN (again, today!) and also from @AstraZeneca: DESTINY-Lung04 Phase III trial showed T-DXd (trastuzumab deruxtecan) PFS > chemo+pembro in FIRST-LINE metastatic HER2-mutant lung cancer (2-4% of all NSCLC) https://t.co/C86sHsx0jN @OncoAlert @OpenMedicineHQ https://t.co/j8VOYZjWAR
𝕏HER2-mutant NSCLC is rapidly becoming a truly targetable disease DESTINY-Lung04 trial to show that upfront HER2-directed T-DXd improves PFS over pembro +chemo The key question now is sequencing: ADC first, or the emerging HER2-selective TKIs? OS and full data will matter. https://t.co/DrR4ebk274
𝕏Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial. https://t.co/AaHX1LPrla
𝕏“The DESTINY-Lung04 data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.” “The trial will continue as planned to evaluate secondary endpoints including overall survival.” https://t.co/2pOoc4jXxd
𝕏Three first-line trials, DESTINY-LUNG04, BEAMION-LUNG02 & SOHO-02, are redefining the HER2-mutant NSCLC landscape. At ILCS 2025, @stephanieplsaw asked how we’ll decide the “winner” if all three outperform Keynote-189: PFS, OS, CNS efficacy, toxicity, or timing of approval? Watch her full talk: https://t.co/qBfsppMWQK Results from BEAMION-LUNG01 (LBA74) & SOHO-01 (LBA75) will offer more insights at #ESMO25. Don’t miss it – add this and other key abstracts to your calendar 👇 https://t.co/50RRVPuS18
𝕏@TumorBoardTues @riess_md @IntegrityCE @DrSanjayPopat @stephanieplsaw @StephenVLiu @LeXiuning @NarjustFlorezMD @SukiPaddaMD @JoelNealMD @Latinamd @jillfeldman4 @Exon20Group @drgandara @LeciaSequist @marinagarassino @peters_solange 21/25 #TumorBoardTuesday 👏Lots of progress for HER2 ex20ins 🫁. More to come! 1️⃣ 1L Anti-HER2 🔹 Ph 3 Beamion LUNG-2: Zongertinib (NCT06151574) 🔹 Ph 3 SOHO-02: Sevabertinib (NCT06452277) 🔹 Ph 3 DESTINY-Lung04: T-DXd (NCT05048797) ➡️ Control=plat/pemetrexed/pembro in all
𝕏🔥DESTINY-Lung04: "Statistically significant and clinically meaningful improvement in PFS" 🆙 @AstraZeneca @DaiichiSankyo 👥Patients: HER2 exon19/20-mutant, unresectable/locally advanced or metastatic non-squamous NSCLC, 1st-line 3⃣Phase III ⚖️Trastuzumab deruxtecan ⚖️Platinum-pemetrexed doublet + pembrolizumab 🔢NCT05048797 #LCSM @OncoAlert @Larvol 🔗 https://t.co/jWxU9lCT3T
𝕏Re- Destiny-Lung04, Phase III of T-DXd vs Chemo in HER2-mutated NSCLC . Big news, although these results anticipated. Will it translate into improved overall survival? https://t.co/28MVd2vhae
𝕏🔔 Destiny-lung04 press release: First proof of evidence that HER2-directed therapies are improving outcomes vs SoC in 1L HER2-mutant NSCLC . Ongoing studies are exploring TDXd in 1L using HER2 IHC and PDL1<50% as biomarkers ( Destiny Lung-06) #some #LCSM https://t.co/08I8k0yno0
About the DESTINY-Lung04 Trial
HER2 (ERBB2) mutations drive roughly 2–4% of nonsquamous NSCLC, disproportionately in younger patients and never-smokers, and until recently had no targeted first-line option: standard care has been PD-(L)1 immunotherapy with or without platinum chemotherapy. Enhertu — a HER2-directed antibody-drug conjugate — changed the treated-disease landscape via DESTINY-Lung02, which earned FDA accelerated approval in previously treated HER2-mutant NSCLC. DESTINY-Lung04 asks the next question: should it move to first line?
On August 17, 2026 — the same morning AstraZeneca announced SAFFRON’s positive readout — Daiichi Sankyo and AstraZeneca reported that T-DXd significantly improved PFS over platinum–pemetrexed plus pembrolizumab. Physicians on this page called it the first proof that HER2-directed therapy beats standard of care up front, while noting what remains open: overall survival is still maturing, and the oral HER2 TKIs zongertinib (Beamion LUNG-2) and sevabertinib (SOHO-02) are running Phase 3 trials against the same control — a sequencing debate the IASLC comparison slide on this page lays out.
Trial Methodology & Results
Study Design
Global, randomized (1:1), open-label Phase 3; actual enrollment 454 (ClinicalTrials.gov; ~264 originally planned). Randomization stratified by smoking history and presence/history of brain metastasis.
Population
Treatment-naive (advanced setting), unresectable locally advanced or metastatic non-squamous NSCLC with HER2 exon 19 or 20 mutation; no other targetable oncogenic alterations.
Interventions
Arm 1: T-DXd (trastuzumab deruxtecan) 5.4 mg/kg. Arm 2: standard of care — platinum (cisplatin or carboplatin) + pemetrexed + pembrolizumab.
Endpoints
Primary: PFS by BICR. Secondary: OS, investigator PFS, ORR, DoR (BICR and investigator), PK, patient-reported tolerability, immunogenicity, safety.
Biomarker
HER2 (ERBB2) exon 19 or 20 activating mutation.
Sponsor
AstraZeneca (ClinicalTrials.gov sponsor) with Daiichi Sankyo as collaborator; Enhertu was discovered by Daiichi Sankyo and is jointly developed and commercialized by both companies.
Efficacy — topline only
T-DXd delivered a statistically significant and clinically meaningful improvement in PFS (primary endpoint, BICR) versus platinum–pemetrexed plus pembrolizumab. No hazard ratios, medians, or response rates have been disclosed; full data are expected at an upcoming medical meeting. The trial continues as planned, with overall survival among the maturing secondary endpoints.
First HER2-directed medicine to beat global 1L standard of care in Phase 3Source: Daiichi Sankyo press release, Aug 17, 2026
Safety
Per the topline announcement, the safety profile of Enhertu in DESTINY-Lung04 was generally consistent with its known profile, with no new safety concerns identified; full quantitative data are expected with the presentation. In the previously treated setting (DESTINY-Lung02, 5.4 mg/kg), the notable T-DXd risk highlighted at IASLC 2026 was ILD in 13% of patients (2% grade ≥3) — prior-line data, not DESTINY-Lung04 data.
Daiichi Sankyo PR, Aug 17, 2026 · IASLC 2026 comparison slide (OCR above)Clinical Implications
⚠ First-line T-DXd in HER2m NSCLC is investigational pending full data and regulatory review. ✅ Enhertu remains FDA-approved (accelerated) in previously treated HER2-mutant disease. If the PFS benefit holds up with OS and tolerability, the 1L treatment paradigm for HER2-mutant NSCLC would shift from chemo-immunotherapy to targeted therapy — with sequencing against the oral HER2 TKIs (zongertinib approved Feb 2026 in later lines; Beamion LUNG-2 and SOHO-02 pending) as the next debate.
Source: FDA approval notificationsDESTINY-Lung04 in the News
DESTINY-Lung04 FAQ
What is the DESTINY-Lung04 trial?
DESTINY-Lung04 (NCT05048797) is a global, randomized (1:1), open-label Phase 3 trial testing Enhertu (trastuzumab deruxtecan, T-DXd) as FIRST-LINE treatment versus the global standard of care - platinum (cisplatin or carboplatin) plus pemetrexed plus pembrolizumab - in patients with unresectable, locally advanced or metastatic non-squamous NSCLC harboring a HER2 exon 19 or 20 mutation. It is the first head-to-head trial of a HER2-directed therapy against standard of care in this first-line setting. ClinicalTrials.gov lists actual enrollment of 454 patients.
What did the DESTINY-Lung04 topline results show?
Per the August 17, 2026 announcement from Daiichi Sankyo and AstraZeneca, Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (the primary endpoint, assessed by blinded independent central review) versus standard of care. Numeric results have not been disclosed; the data will be presented at an upcoming medical meeting and shared with global regulatory authorities, and the trial continues as planned.
Is Enhertu approved for HER2-mutant lung cancer?
Yes - for previously treated disease: Enhertu holds FDA accelerated approval for adults with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations after a prior systemic therapy (based on DESTINY-Lung02 and/or DESTINY-Lung05), and a separate accelerated approval for previously treated HER2-positive (IHC 3+) solid tumors with no satisfactory alternative treatment options. The FIRST-LINE use studied in DESTINY-Lung04 is investigational.
Who is eligible in DESTINY-Lung04?
Adults with treatment-naive (in the advanced setting), unresectable, locally advanced or metastatic non-squamous NSCLC with a HER2 exon 19 or 20 mutation and no other targetable oncogenic alterations.
Why does DESTINY-Lung04 matter?
HER2-mutant NSCLC often affects younger patients and historically lacked a targeted first-line option - standard first-line care has been immunotherapy with or without chemotherapy. DESTINY-Lung04 is the first Phase 3 trial to show a PFS benefit for a HER2-directed medicine over that global standard in first line, and it lands in an increasingly competitive space alongside the oral HER2 TKIs zongertinib (Beamion LUNG-2) and sevabertinib (SOHO-02), both also in Phase 3 against the same control.